Volastra
Ms. Peterson joined CD&R in 2019. Prior to CD&R, she was group worldwide chairman of Johnson & Johnson, where she led the consumer and medical devices businesses and was responsible for the corporation’s global supply chain, as well as its technology strategy and operating infrastructure. Previously, Ms. Peterson served as CEO of Bayer CropScience AG, CEO of Bayer Medical Care, and president of Bayer HealthCare AG’s Diabetes Care Division. She started her career at McKinsey and has held executive positions at Medco Health Solutions (formerly known as Merck-Medco), Nabisco, and Whirlpool. Ms. Peterson is a member of the Microsoft Board of Directors, is Chairman of the Board of the American Academy in Berlin, and is on the board of trustees of the Institute for Advanced Study, the world-renowned center for science and humanities research in Princeton, NJ. Ms Peterson is also on the board of two early stage lifescience companies: Zymergen and Volastra. She has appeared on Fortune magazine’s list of most powerful women numerous times and was featured on the magazine’s inaugural list of leaders changing healthcare.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Volastra
1 followers
Volastra Therapeutics, Inc., is developing novel therapies to treat and prevent the formation of metastatic disease. Launched from the laboratory of Dr. Lewis Cantley, along with Drs. Olivier Elemento and Samuel Bakhoum, Volastra has identified the mechanisms by which CIN drives the formation and proliferation of metastases. Following initial evidence that a patient’s CIN status is prognostic for metastasis and that CIN alters metastasis and overall survival in mouse models, the company is discovering mechanisms and pathways by which CIN modulates metastatic disease to develop novel therapeutics.